<DOC>
	<DOC>NCT01944683</DOC>
	<brief_summary>The study will examine midazolam pharmacokinetics following single dose administration of 3 planned dose levels of GGF2 .</brief_summary>
	<brief_title>A Double-Blind Pharmacokinetic Interaction Study Evaluating the Effect of a Single IV Infusion of GGF2 or Placebo on Midazolam Pharmacokinetics in Patients With Heart Failure</brief_title>
	<detailed_description>This drug-drug interaction (DDI) study evaluates the potential effect of intravenously administered GGF2 on the elimination kinetics of midazolam.</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>If female, must be at least 2 years postmenopausal or have bilateral oophorectomy, hysterectomy or documented sterility If male, must have documented sterility (by verbal report or previous vasectomy), or if nonsterile, must agree to use barrier contraception for the entire duration of the trial and until 3 months after the last dose of investigational product. Must also agree not to donate sperm during the study and up to 3 months after the last dose of investigational product Stable coronary disease without unstable angina or acute coronary syndrome in the last 6 months All cardiac medications, specifically betablockers, reninangiotensin system inhibitors, aldosterone antagonists, hydralazine and nitrates are at a stable dose (at least 4 weeks) prior to Day 1 Any previous exposure to GGF2 or other neuregulins Initiation or change of a prescription medication within the 2 weeks prior to Day 1, and/or concomitant medication regimen is expected to change during the course of the study Known allergic reaction to midazolam, or any of the components of midazolam syrup (including cherry flavoring), or components of GGF2 diluent Known specific hepatic disease; total bilirubin &gt;2 mg/dL, AST &gt; 100 IU History of hepatic impairment (hepatitis B and C) Type I Diabetes Documented stroke or transient ischemic attack (TIA) within 2 months of study enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>